Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study
acelERA Breast Cancer is a randomised, open-label, phase 2 study of giredestrant versus physician choice of endocrine therapy in post- or pre-/peri-menopausal women, and men with oestrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. Data from the primary analysis are reported.